Your browser doesn't support javascript.
loading
Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model.
Fang, Tracy-Shi Zhang; Sun, Yu; Pearce, Andrew C; Eleuteri, Simona; Kemp, Mark; Luckhurst, Christopher A; Williams, Rachel; Mills, Ross; Almond, Sarah; Burzynski, Laura; Márkus, Nóra M; Lelliott, Christopher J; Karp, Natasha A; Adams, David J; Jackson, Stephen P; Zhao, Jin-Feng; Ganley, Ian G; Thompson, Paul W; Balmus, Gabriel; Simon, David K.
Afiliação
  • Fang TZ; Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. szhang9@bidmc.harvard.edu.
  • Sun Y; UK Dementia Research Institute at the University of Cambridge and Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0AH, UK.
  • Pearce AC; Mission Therapeutics Ltd. Glenn Berge Building, Babraham Research Campus, Cambridge, CB22 3FH, UK.
  • Eleuteri S; Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
  • Kemp M; Mission Therapeutics Ltd. Glenn Berge Building, Babraham Research Campus, Cambridge, CB22 3FH, UK.
  • Luckhurst CA; Mission Therapeutics Ltd. Glenn Berge Building, Babraham Research Campus, Cambridge, CB22 3FH, UK.
  • Williams R; Mission Therapeutics Ltd. Glenn Berge Building, Babraham Research Campus, Cambridge, CB22 3FH, UK.
  • Mills R; Mission Therapeutics Ltd. Glenn Berge Building, Babraham Research Campus, Cambridge, CB22 3FH, UK.
  • Almond S; Mission Therapeutics Ltd. Glenn Berge Building, Babraham Research Campus, Cambridge, CB22 3FH, UK.
  • Burzynski L; Mission Therapeutics Ltd. Glenn Berge Building, Babraham Research Campus, Cambridge, CB22 3FH, UK.
  • Márkus NM; Mission Therapeutics Ltd. Glenn Berge Building, Babraham Research Campus, Cambridge, CB22 3FH, UK.
  • Lelliott CJ; Wellcome Sanger Institute, Cambridge, CB10 1SA, UK.
  • Karp NA; Wellcome Sanger Institute, Cambridge, CB10 1SA, UK.
  • Adams DJ; Wellcome Sanger Institute, Cambridge, CB10 1SA, UK.
  • Jackson SP; Mission Therapeutics Ltd. Glenn Berge Building, Babraham Research Campus, Cambridge, CB22 3FH, UK.
  • Zhao JF; The Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QN, UK.
  • Ganley IG; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0RE, UK.
  • Thompson PW; MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, DD1 5EH, UK.
  • Balmus G; MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, DD1 5EH, UK.
  • Simon DK; Mission Therapeutics Ltd. Glenn Berge Building, Babraham Research Campus, Cambridge, CB22 3FH, UK. PThompson@missiontherapeutics.com.
Nat Commun ; 14(1): 7295, 2023 11 13.
Article em En | MEDLINE | ID: mdl-37957154
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Tioléster Hidrolases Limite: Animals Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Tioléster Hidrolases Limite: Animals Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos